Literature DB >> 33397486

Differences between memory encoding and retrieval failure in mild cognitive impairment: results from quantitative electroencephalography and magnetic resonance volumetry.

Su-Hyun Han1, Jung-Min Pyun2, Soeun Yeo1, Dong Won Kang3, Ho Tae Jeong1, Seung Wan Kang4,5, SangYun Kim2, Young Chul Youn6,7.   

Abstract

BACKGROUND: The memory impairments in mild cognitive impairment (MCI) can be classified into encoding (EF) and retrieval (RF) failure, which can be affected by underlying pathomechanism. We explored the differences structurally and functionally.
METHODS: We compared quantitative electroencephalography (qEEG) power spectra and connectivity between 87 MCI patients with EF and 78 MCI with RF using iSyncBrain® (iMediSync Inc., Republic of Korea) ( https://isyncbrain.com/ ). Voxel-based morphometric analysis of the gray matter (GM) in the MCI groups and 71 cognitive normal controls was also done using the Computational Anatomy Toolbox 12 ( http://www.neuro.uni-jena.de/cat/ ).
RESULTS: qEEG showed higher frontal theta and lower beta2 band power, and higher theta connectivity in the EF. There was no statistically significant difference in GM volume between the EF and RF. However, when compared to normal control, GM volume reductions due to EF in the left thalamus and bilateral hippocampi and reductions due to RF in the left thalamus, right superior frontal lobe, right superior temporal lobe, and right middle cingulum were observed (p < 0.05, family-wise error correction).
CONCLUSIONS: MCI differs functionally and structurally according to their specific memory impairments. The EF findings are structurally and functionally more consistent with the prodromal Alzheimer's disease stage than the RF findings. Since this study is a cross-sectional study, prospective follow-up studies are needed to investigate whether different types of memory impairments can predict the underlying pathology of amnestic MCI. Additionally, insufficient sample size may lead to ambiguous statistical findings in direct comparisons, and a larger patient cohort could more robustly identify differences in GM volume reductions between the EF and the RF group.

Entities:  

Keywords:  EEG; Encoding; MRI; Mild cognitive impairment; Retrieval; Voxel-based morphometry; qEEG

Mesh:

Year:  2021        PMID: 33397486      PMCID: PMC7784298          DOI: 10.1186/s13195-020-00739-7

Source DB:  PubMed          Journal:  Alzheimers Res Ther            Impact factor:   6.982


  45 in total

1.  Standardized low-resolution brain electromagnetic tomography (sLORETA): technical details.

Authors:  R D Pascual-Marqui
Journal:  Methods Find Exp Clin Pharmacol       Date:  2002

2.  Identifying true brain interaction from EEG data using the imaginary part of coherency.

Authors:  Guido Nolte; Ou Bai; Lewis Wheaton; Zoltan Mari; Sherry Vorbach; Mark Hallett
Journal:  Clin Neurophysiol       Date:  2004-10       Impact factor: 3.708

Review 3.  Memory Dysfunction.

Authors:  G Peter Gliebus
Journal:  Continuum (Minneap Minn)       Date:  2018-06

4.  Longitudinal change of biomarkers in cognitive decline.

Authors:  Raymond Y Lo; Alan E Hubbard; Leslie M Shaw; John Q Trojanowski; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust
Journal:  Arch Neurol       Date:  2011-06-13

5.  Serial MRI and CSF biomarkers in normal aging, MCI, and AD.

Authors:  P Vemuri; H J Wiste; S D Weigand; D S Knopman; J Q Trojanowski; L M Shaw; M A Bernstein; P S Aisen; M Weiner; R C Petersen; C R Jack
Journal:  Neurology       Date:  2010-07-13       Impact factor: 9.910

6.  Decreased Parietal Beta Power as a Sign of Disease Progression in Patients with Mild Cognitive Impairment.

Authors:  Christian Sandøe Musaeus; Malene Schjønning Nielsen; Natascha Nellum Østerbye; Peter Høgh
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  EEG coherence in Alzheimer's dementia.

Authors:  G Adler; S Brassen; A Jajcevic
Journal:  J Neural Transm (Vienna)       Date:  2003-09       Impact factor: 3.575

8.  EEG Theta Power Is an Early Marker of Cognitive Decline in Dementia due to Alzheimer's Disease.

Authors:  Christian Sandøe Musaeus; Knut Engedal; Peter Høgh; Vesna Jelic; Morten Mørup; Mala Naik; Anne-Rita Oeksengaard; Jon Snaedal; Lars-Olof Wahlund; Gunhild Waldemar; Birgitte Bo Andersen
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  The Effect of a Virtual Reality-Based Intervention Program on Cognition in Older Adults with Mild Cognitive Impairment: A Randomized Control Trial.

Authors:  Ngeemasara Thapa; Hye Jin Park; Ja-Gyeong Yang; Haeun Son; Minwoo Jang; Jihyeon Lee; Seung Wan Kang; Kyung Won Park; Hyuntae Park
Journal:  J Clin Med       Date:  2020-04-29       Impact factor: 4.241

Review 10.  Neurophysiological Markers of Alzheimer's Disease: Quantitative EEG Approach.

Authors:  Una Smailovic; Vesna Jelic
Journal:  Neurol Ther       Date:  2019-12-12
View more
  4 in total

Review 1.  Salient Cognitive Paradigms to Assess Preclinical Alzheimer's Disease.

Authors:  Rosie E Curiel Cid; David A Loewenstein
Journal:  Neurotherapeutics       Date:  2022-03-04       Impact factor: 6.088

2.  Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer's Disease.

Authors:  Chiara Fornari; Francesco Mori; Nicola Zoppi; Ilenia Libri; Chiara Silvestri; Maura Cosseddu; Rosanna Turrone; Matteo Maffi; Salvatore Caratozzolo; Barbara Borroni; Alessandro Padovani; Alberto Benussi
Journal:  Neurol Int       Date:  2022-04-06

3.  Donepezil for mild cognitive impairment in Parkinson's disease.

Authors:  Kyoungwon Baik; Seon Myeong Kim; Jin Ho Jung; Yang Hyun Lee; Seok Jong Chung; Han Soo Yoo; Byoung Seok Ye; Phil Hyu Lee; Young H Sohn; Seung Wan Kang; Suk Yun Kang
Journal:  Sci Rep       Date:  2021-02-26       Impact factor: 4.379

4.  Power Spectral Changes of Quantitative EEG in the Subjective Cognitive Decline: Comparison of Community Normal Control Groups.

Authors:  Ho Tae Jeong; Young Chul Youn; Hyun-Ho Sung; Sang Yun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-24       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.